Opening Hook
When a Bhopal-based molecular diagnostics firm starts casually buying a 30-year-old Belgian rapid test company, you know things are getting international. 3B BlackBioDx (formerly Kilpest) reported Q1FY26 sales of ₹19.96 crore (+18% YoY), EBITDA of ₹16.2 crore (after one-offs ~17% growth), and is now flaunting a global ambition: Coris Bioconcept acquisition, AMR test pipeline, and Europe/US expansion. Investors wanted clarity; management served a full-course meal of MDX jargon, R&D flex, and “don’t worry, margins are still 55–60%.”

At a Glance
• Q1 Sales ₹19.96 Cr (+18% YoY)
• EBITDA ₹16.2 Cr (ex-M&A costs ~17% YoY growth)
• Market share 12–15% in Indian MDX industry (₹350–450 Cr market)
• Growth guidance: India 15–20%, Exports 20–25%
• Coris Acquisition: €5.2M sales, 58.7% GM, slight EBITDA loss
• Exports share: 17–18% → guided to 35–40% in 5 years

Management’s Key Commentary

• “We are market leaders with 12–15% share in Indian MDX.”
  Translation: A small pond, but we’re the big fish.
• “Coris brings AMR products where only 2–3 global players exist.”
  Translation: We couldn’t make these antibodies ourselves, so we bought the chef.
• “EBITDA margins at 55–60% may compress to ~55% due to wage inflation and competition.”
  Translation: Still insanely fat margins compared to most Indian companies.

Numbers Decoded

Analyst Q&A Highlights
Q: Why do some MDX firms earn fat margins, others not?
Mgmt: “Depends on manpower & cost base. Ours is low-cost India advantage.”
Translation: Cheap PhDs, great EBITDA.

Q: Process to win diagnostic lab clients?
Mgmt: “Demo → validation → negotiation → onboarding. 3–6 months cycle.”
Translation: Convince the lab head scientist, then deal with bean counters.

Q: Coris EBITDA negative, what’s the plan?
Mgmt: “Scale AMR products, US FDA approval, cross-sell